ArticleBMC pharmacology & toxicology2025
Berberine and berberrubine promote the expression of CYP3A4 via enhancing the binding of nuclear receptor PXR.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification-A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBerberine is currently co-administered with statins in clinical practice for hyperlipidemia management. This study aimed to investigate the effects of berberine and berberrubine on CYP3A4 expression and the regulatory mechanism.
methodsUsing rifampicin as a positive control group, HepG2 cells were treated with different concentrations of berberine and berberrubine. Q-PCR was employed to detect the expression levels of CYP3A4 mRNA in response to the drugs, and Western blot was utilized to determine the expression of CYP3A4 and PXR proteins. Dual luciferase reporter gene assay and RNA interference technology were used to silence PXR to explore the mechanism of berberine and berberrubine regulation of CYP3A4.
resultsCompared with the blank control group, both berberine and berberrubine could induce CYP3A4 mRNA expression in a concentration-dependent manner (P < 0.05). After treatment with 50 µM berberine and 60 µM berbamine for 48 h, the expression of CYP3A4 in HepG 2 cells was increased by 2.5 and 2.7 times, respectively. Berberine (10 ~ 50 µM) and berberrubine (15 ~ 60 µM) could upregulate the expression of PXR nuclear protein in a dose-dependent manner. Berberine and berbamine at different concentrations significantly upregulated the activity of the dual luciferase constructed based on PXR (P < 0.05), while silencing PXR reduced the inductive effects of berberine and berbamine on CYP3A4. Berberine and berbamine at different concentrations significantly upregulated the activity of the dual luciferase constructed based on PXR (P < 0.05), while silencing PXR reduced the inductive effects of berberine and berbamine on CYP3A4.
conclusionBerberine and berberrubine can promote the expression of CYP3A4 protein in HepG2 cells by inducing the nuclear receptor PXR to bind to the promoter of CYP3A4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.